Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Merck's profit jumps 12% on 24% sales increase

Article Abstract:

Merck & Co. posted an improvement of 12% in net income for the second-quarter of 1999. The company's income were what analysts had expected. Merck benefited from strong osteoporosis, high-blood pressure, and arthritis drug sales. The company reported $1.48 billion (1.41 billin euros) in net income for the quarter. Merck's sales also improved 24% to $8.02 billion.

Comment:

Posts improvement of 12% in net income for second-quarter of 1999

Author: Langreth, Robert
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
United States, Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Finance, Abstract, Merck & Company Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


AstraZeneca says it expects to meet annual forecast

Article Abstract:

AstraZeneca PLC predicted that it will meet its yearly targets for the 2001 year. The company has been performing well during the 2001 year as of the month of December.

Author: Rodgers, Susannah
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
United Kingdom, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Forecasts and trends, AstraZeneca PLC, AZN

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Pharmaceutical industry, Drugs
Similar abstracts:
  • Abstracts: Letsbuyit expects losses to narrow. Barnes & Noble.com expects to report 23% revenue rise. Barnes & Noble warns that profit will miss target
  • Abstracts: Intel's profit leaps 57% in quarter. Agere repays part of debt
  • Abstracts: Novartis's net profit rises 13%, driven by a 19% sales increase. Swiss Life Shares Will Be Comatose Until Markets Revive
  • Abstracts: SkyePharma's loss widened in first half. Bioglan's wrangling may be tied to deal
  • Abstracts: Air France's earnings soared in quarter. KLM Airlines adds surcharge to offset costs. French Concordes will continue to be grounded
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.